Femasys vs Volitionrx
Femasys is the larger business, with $2.3m of revenue in fiscal 2025 against $1.7m for Volitionrx (1.3 times as much). Femasys grew faster (40.8% against 40.0%). Femasys kept more of each dollar of sales as profit: a net margin of -812.3% against -1352.2%.
| Latest fiscal year | FemasysFEMY, 2025 | VolitionrxVNRX, 2025 |
|---|---|---|
| Revenue | $2.3m | $1.7m |
| Revenue growth | 40.8% | 40.0% |
| Net income | −$18.6m | −$23.4m |
| Operating margin | -767.0% | -1258.5% |
| Net margin | -812.3% | -1352.2% |
| Return on equity | — | — |
| Free cash flow | −$19.2m | −$19.8m |
| Cash | $9.3m | $1.1m |
| Total debt | $3.2m | $8.2m |
| Debt to equity | 54.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 51 | — |
| Market value | $4.1m | $2.3m |
| Price vs our value range | — | — |
| Moat score | 37 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 0 sales |